Sun Pharma Acquires 100% Stake in Antibe Therapeutics for CAD 4.5 Million

TARO Pharmaceuticals Inc. a subsidiary of Sun Pharmaceutical Industries Ltd, India's largest pharmaceutical firm, has completed the acquisition of Antibe Therapeutics, a Canadian drug development firm, for CAD 4.5 million (around ₹27 crore). The strategic acquisition is to strengthen Sun Pharma's pipeline of new therapies.

 

Highlights:

The transaction offers the company's access to Antibe's patented hydrogen sulfide-releasing technology, which has the potential to treat chronic pain and inflammatory diseases. The acquisition is likely to improve Sun Pharma's R&D capabilities and increase its portfolio in overseas markets.

 

Dilip Shanghvi, Sun Pharma's Managing Director, said, "This acquisition continues our focus on investing in innovation and meeting unmet medical needs."

 

Sources: Sun Pharma Press Release, Business Standard, March 18, 2025